Screener
ADMA Biologics ADMA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $$31,724 | 22,519 |
| Accrued expenses and other current liabilities | 39,105 | 40,466 |
| Current portion of long-term debt | 3,750 | 2,813 |
| Current portion of lease obligations | 1,178 | 1,096 |
| Liabilities held for sale | - | 2,647 |
| Total current liabilities | 75,757 | 69,541 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's accrued expenses?
- ADMA Biologics (ADMA) reported accrued expenses of $39.11M in Q2 2026.
- How has ADMA Biologics's accrued expenses changed year-over-year?
- ADMA Biologics's accrued expenses decreased by 10.9% year-over-year, from $43.9M to $39.11M.
- What is the long-term trend for ADMA Biologics's accrued expenses?
- Over 5 years (2020 to 2025), ADMA Biologics's accrued expenses has grown at a 37.1% compound annual growth rate (CAGR), from $8.37M to $40.47M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about ADMA Biologics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude